Finshots Daily
Original podcast
Where to listenCopy share link
In today’s episode on 1st July 2025, we talk about Amazon’s foray into India’s diagnostics space and whether it can disrupt the industry.
1,143 words · 1 speaker
Hello folks, you're listening to Finshots Daily. In today's episode, we talk about Amazon's foray into India's diagnostic space and whether it can disrupt the industry.
A quick announcement before we begin. Finshots and Ditto are hiring across a bunch of marketing roles. So if you're into content, design, SEO or influencer marketing and you actually enjoy working on meaningful, creative stuff, we'd love to have you. The team's young, fun and genuinely collaborative. You will find the link to apply in the episode description or you can head to joinditto.in. Come join us. And now, here's today's story. Over the past week, you might have noticed something interesting. Shares of India's diagnostic companies have taken a bit of a tumble. Stocks like Sweraksha Diagnostics, Krishna Diagnostics, Tyrocare Technologies, Metropolis and Dr. Lal Path Labs slipped by up to 2% even as the broader market moved in the opposite direction.
And you've probably guessed what's booked investors this time. But if you haven't, well, Amazon just threw its hat into India's diagnostics ring. It's now offering at-home test collections, digital reports and bundled health services across six cities covering 450 pin codes. The buzz is that it could shake things up in a big way. But here's the thing. This isn't Amazon's first rodeo in Indian healthcare. It's already dipped its toes into e-farmacies and online consultations. Sure, those services are still around, but let's be honest. They haven't exactly set the world on fire. It's more of a work in progress than a roaring success. So why is Amazon doubling down and adding new pieces to its healthcare puzzle when it hasn't really cracked the code yet?
Well, the simplest answer is that it already had e-farmacies. But to figure out what to sell, it needed to know why people were buying medicines in the first place. That's where online consultations come in handy. People could talk to doctors from home, get prescriptions and Amazon could plug into that system, supplying medicines and figuring out which pharmacy partners to work with in each region. But what happens when a doctor suggests a blood test? People typically head to the nearest lab or get it done through a hospital. That's a piece of the puzzle Amazon didn't have, so diagnostics felt like a natural extension. And when you zoom out, the diagnostic space in India does look like a ripe opportunity. For context, right now, hospital labs control about thirty-eight percent of the market.
Standalone diagnostic centers take thirty-seven percent and the big branded chains, the likes of Dr. Lalpath Labs and Thyrocare, hold the remaining twenty-two percent. But rewind to five years ago and the picture looked different. Back then, standalone labs dominated nearly half the market while big chains held just a measly fifteen percent. Clearly, the winds have shifted. But why? Because starting a small diagnostic lab in India isn't all that hard. You don't need fancy equipment or major infrastructure. Regulatory checks are minimal, national accreditations are mandatory, and many labs operate without formal registration under the Clinical Establishments Act, which isn't enforced in most states anyway.
In fact, some labs even get by without trained pathologists or microbiologists on site. That makes it easy to enter but tough to trust. And when it comes to health, trust matters. Patients are increasingly leaning towards branded labs that offer standardized procedures, reliable results, and professional staff. That's why chains have been gaining ground. They're able to invest in better equipment, train professionals, and expansion, all while maintaining consistency across locations. Add to that the growing demand and diagnostics starts to look like a sweet spot. The Indian diagnostics market was worth eighteen billion dollars in FY24 and could nearly double to thirty-five billion dollars by FY30. Operating profit margins are healthy too, around thirty percent in FY24, even though
they've been weighed down a bit by the cost of digitization and customer acquisition. Naturally, Amazon's been paying close attention to all of this. Plus, it has the money, it has a trusted brand, it already owns an Indian delivery network and knows how to handle logistics. And now, it doesn't even need to build everything from scratch. Instead, it's partnering with Bengaluru-based startup Orange Health Labs, an accredited diagnostics platform backed by big investors like Axel, Y Combinator and General Catalyst. Customers can choose from over 800 tests, get a sample collected from their home in as little as 60 minutes and receive reports within six hours and that's for most routine tests. It's fast, digital and designed for convenience.
Well, this is the way Amazon likes it. But we know what you're thinking. Why partner with a relatively small startup instead of a big-name diagnostics chain? Maybe it's because startups are hungrier. They're often more agile, focused on user experience and eager to build trust from the ground up. Exactly the kind of partner Amazon would need if it wants to scale quickly and win customer loyalty. But even with all that firepower, can Amazon actually disrupt diagnostics in India, you ask? Well, that's actually the tricky part. As Amazon India's Director Medical Jayarama Krishnan Balasubramanian puts it in his media interviews, "The goal is to make people trust diagnostics the same way they once learned to trust online shopping."
But health isn't quite like ordering a pair of headphones. Because just think about it. You usually see a doctor only when something feels off and for common stuff like a cold or fever, tests aren't always necessary. When it is serious, you're more likely to head to a hospital just in case you need to get admitted. You wouldn't want to book a test through Amazon and then run to the ER, that is, emergency room later. It just feels inconvenient. Which means, Amazon's diagnostics model will likely lean heavily on preventive healthcare or getting tests done before something goes wrong. But that's a tough sell in India. Look, preventive healthcare still has low penetration here. Most people think, "Why spend money when I'm not sick?" It's the same mindset that plagues insurance.
And while Amazon may have excellent customer service, changing this behaviour won't be easy. Especially when the average Indian spends less than $15 a year on preventive healthcare compared to over $2,000 in the US.
Competition for Amazon's diagnostics play probably isn't the diagnostic chains. It's actually the hospitals. After all, when things get serious, people still trust their local hospital more than an app. And the only way Amazon could truly go toe to toe with that is if it builds its own hospitals someday. Now, will it take that leap? Well, that's anyone's guess for now. Thank you for listening to today's episode. And if you want to share your feedback or suggestions, do drop us an email to [email protected]. Until next time.
Page updated November 11, 2026 · transcript and summary are machine-generated